Seagen Inc. (SGEN) Stock Valuation — DCF Analysis
Biotechnology · NASDAQ
Current Price
$228.74
Intrinsic Value
Use the calculator below to estimate
COMPETITIVE MOAT
↑ADC Technology Leadership
Seagen possesses deep expertise in antibody-drug conjugate (ADC) technology. This specialized knowledge allows for the development of highly targeted cancer therapies.
↑Pipeline of Novel Therapies
A robust pipeline of innovative drug candidates across various cancer types provides future growth potential. This diversification mitigates reliance on single products.
↑Strong Clinical Trial Execution
Proven ability to successfully navigate complex clinical trials and gain regulatory approvals. This demonstrates operational excellence and scientific rigor.
INVESTMENT RISKS
↓Intense Competition
The biotechnology sector is highly competitive with numerous companies developing similar therapies. This can lead to pricing pressures and market share challenges.
↓Regulatory Hurdles
Drug development is subject to stringent and evolving regulatory requirements. Delays or rejections in approvals can significantly impact timelines and revenue.
↓Patent Expirations
Loss of patent protection for key drugs will open the door to generic competition. This necessitates continuous innovation and pipeline replenishment.
Customize the SGEN valuation
Adjust the growth rate, discount rate, and exit multiple to see how the intrinsic value and margin of safety for Seagen Inc. respond.
Open DCF Calculator for SGENCompany Overview
Seagen Inc. is a biotechnology firm focused on the development and global commercialization of innovative cancer treatments. Its portfolio features several key oncology therapeutics, including ADCETRIS, an antibody-drug conjugate (ADC) utilized for Hodgkin lymphoma and CD30-positive T-cell lymphomas; PADCEV, another ADC designed to target Nectin-4 in patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor prescribed for adults battling advanced, inoperable, or metastatic HER2-positive breast cancer. Beyond its marketed drugs, Seagen maintains an active pipeline of investigational therapies. These encompass TIVDAK for metastatic cervical cancer and other solid malignancies; Ladiratuzumab Vedotin, an ADC aimed at LIV-1 for metastatic breast cancer and other solid tumors; Disitamab Vedotin, a novel ADC specifically targeting HER2; and preclinical candidates such as SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70, intended for diverse oncological conditions. The company has established strategic alliances with several partners, including Takeda Pharmaceutical Company Limited, Agensys, Inc., Genmab A/S, Merck, and RemeGen, Co. Ltd. Originally incorporated in 1997 as Seattle Genetics, Inc., the firm adopted its current name, Seagen Inc., in October 2020. Its corporate headquarters are located in Bothell, Washington.
Financial Metrics — SGEN Stock Valuation Data
Revenue/Share (TTM)
$10.63
FCF/Share (TTM)
$-2.88
ROIC (TTM)
-21.5%
ROE (TTM)
-20.8%
P/FCF
n/m
EV/EBITDA
-68.8x
FCF Yield
-1.23%
Debt/Equity
0.02x
SGEN currently has negative free cash flow, so cash-flow ratios such as P/FCF and FCF yield do not give a meaningful read on whether the stock is cheap or expensive. A DCF valuation is unreliable until cash generation turns positive — focus on the path to profitability instead.
Frequently Asked Questions
What is the intrinsic value of SGEN?
Seagen Inc. currently generates $-2.88 in free cash flow per share. At the current price of $228.74, a DCF model would discount these cash flows at an appropriate WACC and apply a terminal growth rate to arrive at an intrinsic value. The result depends heavily on your growth and discount rate assumptions — a 1% change in WACC typically shifts the fair value estimate by 10-15%. In MiniValuator the model uses a single discount rate that you can edit directly, 10% by default, rather than a computed WACC.
Is SGEN undervalued?
SGEN currently has negative free cash flow, so its P/FCF ratio is not meaningful and cannot tell you whether the stock is cheap or expensive. With cash flow negative, a DCF-based undervalued or overvalued judgment is unreliable — look at the path back to positive cash generation instead.
How do I value SGEN stock using DCF?
To perform a DCF valuation on Seagen Inc.: (1) Start with the trailing free cash flow per share ($-2.88) as the base, (2) project future FCF growth over 5-10 years based on Biotechnology industry trends and company fundamentals, (3) apply a discount rate (WACC) reflecting SGEN's risk profile — with a debt-to-equity of 0.02x, capital structure is an important factor, and (4) add a terminal value for cash flows beyond the projection period.
What is DCF valuation and how does it apply to SGEN?
DCF (Discounted Cash Flow) estimates what a company is worth today based on its future cash generation. For Seagen Inc., this means projecting how much free cash flow the company will produce over the next 5-10 years, shaped by Biotechnology trends, then discounting those amounts to today's dollars. SGEN's ROIC of -21.5% suggests the company may face challenges generating returns above its cost of capital.
How does WACC affect SGEN stock valuation?
WACC (Weighted Average Cost of Capital) is the discount rate in a DCF model — it reflects the minimum return investors require. For SGEN, with a debt-to-equity ratio of 0.02x, the capital structure directly influences WACC. A 1% increase in WACC typically reduces the intrinsic value by 10-15%. At an EV/EBITDA of -68.8x, the market's implied discount rate can be reverse-engineered for comparison. In MiniValuator you set this discount rate yourself as a single editable number, 10% by default, instead of computing a formal WACC.
Learn More
- See SGEN PE Valuation → — Earnings-based stock valuation using PE ratio analysis
- DCF Methodology — Step-by-step guide to discounted cash flow analysis
- PE Methodology — Guide to PE ratio stock valuation
- WACC — Understanding the discount rate used in DCF
- Margin of Safety — How to evaluate downside protection
- Intrinsic Value — How to evaluate stock fair value
- How to Calculate Intrinsic Value — Complete guide for investors
Related Valuations
All Healthcare valuationsDCF and P/E value SGEN with different methods and assumptions, so the two conclusions can differ. Compare the P/E fair value.
Price as of 2023-12-13. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.